Roche has agreed to purchase US-based Anadys Pharmaceuticals, a specialist in hepatitis C treatments, for around $230m in cash.

Roche’s attraction to Anadys is focused on the company’s ANA598 compound, currently being evaluated in combination with Roche’s Pegasys and Copegus treatments for hepatitis C.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Switzerland-based pharmaceutical firm is paying $3.70 a share, a 256% premium over the $1.04 closing price of Anadys on Friday October 14. The company’s board has advised other stockholders to follow the board’s lead and tender their shares.

Roche pharma research and early development head Jean-Jacques Garaud said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure."

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now